Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT02608268
Title Safety and Efficacy of MBG453 as Single Agent and in Combination With PDR001 in Patients With Advanced Malignancies
Recruitment Terminated
Gender both
Phase Phase Ib/II
Variant Requirements No
Sponsors Novartis Pharmaceuticals
Indications

renal cell carcinoma

lung non-small cell carcinoma

melanoma

Advanced Solid Tumor

Therapies

Spartalizumab

Sabatolimab

Age Groups: adult
Covered Countries USA | ITA | CAN

Facility Status City State Zip Country Details
Sidney Kimmel Comprehensive Cancer Center Johns Hopkins Med Sidney Kimmel CCC Baltimore Maryland 21231 United States Details
Dana Farber Cancer Institute DFCI - Brookline Boston Massachusetts 02215 United States Details
UT M.D Anderson Cancer Center Houston Texas 77030 United States Details
Cancer Therapy and Research Center UT Health Science Center San Antonio Texas 78229 United States Details
Novartis Investigative Site Toronto Ontario M5G 2C1 Canada Details
Novartis Investigative Site Milano MI 20141 Italy Details
Novartis Investigative Site Rozzano MI 20089 Italy Details
Novartis Investigative Site Kashiwa Chiba 277 8577 Japan Details
Novartis Investigative Site Seoul 03080 Korea, Republic of Details
Novartis Investigative Site Amsterdam 1066 CX Netherlands Details
Novartis Investigative Site Leiden 2300 RC Netherlands Details
Novartis Investigative Site Singapore 169610 Singapore Details
Novartis Investigative Site Geneve 14 CH 1211 Switzerland Details
Novartis Investigative Site Taipei 10002 Taiwan Details
*Shaded cells indicate that there was no data available from clincialtrials.gov for the field